Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)資訊與事件

$29.210

0.000 (0.00%)收盤時

HIMS 資訊

HIMS 事件

10/21 08:30

Hims Introduces Injectable and Oral Testosterone Replacement Therapy

Hims is introducing access to injectable and oral testosterone replacement therapy, calling this "the largest and most important expansion to date of our men's health program." In a post, the company stated: "These new options build on Hims' existing Testosterone Rx+ treatment, which includes enclomiphene, an ingredient shown to double testosterone levels^ by boosting the body's natural hormone production. Since introducing its testosterone offering, Hims has focused on reaching the many men living with low T, building an experience around at-home blood collection and provider-guided treatment that adapts over time. That approach is resonating. As of the second quarter, testosterone was scaling faster than any other specialty outside of weight loss, just three quarters after its launch... With injectable and oral testosterone now added to our previously available enclomiphene-based treatments , our partnered clinicians can now offer a full suite of personalized treatments to men affected by low T."

10/20 11:00

Hims and Hers Health Shares Rise 4.33%

Moderately bullish activity in Hims and Hers Health (HIMS), with shares up $1.22, or 4.33%, near $29.37. Options volume relatively light with 12k contracts traded and calls leading puts for a put/call ratio of 0.37, compared to a typical level near 0.44. Implied volatility (IV30) is higher by 2.2 points near 90.22,and above the 52wk median, suggesting an expected daily move of $1.67. Put-call skew steepened, indicating increased demand for downside protection.

10/12 15:30

Hims & Hers Officially Launches Hers in Australia

Hims & Hers announced the official launch of Hers in Australia, bringing its personalized care platform to women nationwide for the first time. The launch introduces treatment programs across hair, menopause and perimenopause, and weight loss care - backed by women's-only research and 24/7 Care Team access. The launch marks the rebrand of Juniper, Eucalyptus' women's health platform, which has served patients in Australia since 2021, to Hers. It follows Pilot's transition to Hims in August and completes Hims & Hers' full platform launch in Australia, building on the company's acquisition of Eucalyptus earlier this year. Current Juniper patients will continue to be supported by the same care team and Australian practitioners.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易